Jim Cramer: These Five Health Stocks to Buy in 2022
These five health care stocks have held steady through 2022 and should be on the buy list next year, according to "Mad Money" host Jim Cramer.
Jim Cramer has announced his new preference for boring stocks several times this year. In tough economic times, it's clear that technology stocks will be left behind by older companies. Time and time again, he mentioned companies in the healthcare sector, such as Johnson & Johnson or Eli Lilly and Co. because the pharmaceutical industry, in particular, is doing particularly well in this time of crisis.
Traditional companies are less driven by competitive pressures and, thanks to autonomous development, are now able to win back the stock market that was dominated by technology stocks during the growth phase. "Wall Street likes profitable companies with stable earnings, strong dividends and reasonably priced stocks," Jim Kramer told investors on his CNBC show "Mad Money" shopping list for 2023.
Shares of Pfizer, the world's largest pharmaceutical company, remain a good value, with Cramer highlighting the acquisitions of Arena Pharmaceuticals, Biohaven and Global Blood Therapeutics.
$Pfizer(PFE.US$ $Johnson & Johnson(JNJ.US$ $Eli Lilly and Co(LLY.US$ $Biohaven(BHVN.US$
Jim Cramer has announced his new preference for boring stocks several times this year. In tough economic times, it's clear that technology stocks will be left behind by older companies. Time and time again, he mentioned companies in the healthcare sector, such as Johnson & Johnson or Eli Lilly and Co. because the pharmaceutical industry, in particular, is doing particularly well in this time of crisis.
Traditional companies are less driven by competitive pressures and, thanks to autonomous development, are now able to win back the stock market that was dominated by technology stocks during the growth phase. "Wall Street likes profitable companies with stable earnings, strong dividends and reasonably priced stocks," Jim Kramer told investors on his CNBC show "Mad Money" shopping list for 2023.
Shares of Pfizer, the world's largest pharmaceutical company, remain a good value, with Cramer highlighting the acquisitions of Arena Pharmaceuticals, Biohaven and Global Blood Therapeutics.
$Pfizer(PFE.US$ $Johnson & Johnson(JNJ.US$ $Eli Lilly and Co(LLY.US$ $Biohaven(BHVN.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
The content is carried from Twitter "Inverse Cramer ETF‘’.
1071Followers
31Following
3327Visitors
Follow
The Value Investor : Cramer has underperformed the market for the past… forever. You’re making me nervous, maybe I should just sell my shares of Pfizer. Cramer is the type of person that I would short anything he touches. He’s the same idiot that called Cathie Woods a genius when her ETF was soaring up, then called her an idiot on the way down. He’s literally just following hype and he sounds like 13 year moron to.
Cramer ETF OP The Value Investor : Do the opposite.